Short Interest in Prenetics Global Limited (NASDAQ:PRE) Grows By 22.1%

Posted by Editorial Team on Mar 7th, 2025

Prenetics Global Limited (NASDAQ:PRE – Get Free Report) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 39,800 shares, a growth of 22.1% from the January 31st total of 32,600 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 14,100 shares, the days-to-cover ratio is presently 2.8 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in Prenetics Global Limited (NASDAQ:PRE – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent reporting period. Institutional investors and hedge funds own 25.01% of the company’s stock.

Prenetics Global Trading Down 0.9 %

Shares of NASDAQ PRE opened at $4.75 on Friday. Prenetics Global has a 12 month low of $2.85 and a 12 month high of $7.84. The firm has a market capitalization of $57.91 million, a price-to-earnings ratio of -1.19 and a beta of -0.31. The business has a 50-day moving average of $5.49 and a 200-day moving average of $5.01.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $9.00 target price on shares of Prenetics Global in a report on Thursday, January 16th.

Get Our Latest Research Report on PRE

Prenetics Global Company Profile

(Get Free Report)

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.